Affiliation:
1. The First Affiliated Hospital of Zhengzhou University
2. Guilin Medical University Affiliated Hospital
Abstract
Abstract
Background
FYN is a nonreceptor tyrosine kinase that regulates diverse pathological processes. The pro-cancer role of FYN in multiple malignancies has been elucidated. However, the mechanisms that FYN promotes gastric cancer(GC) progression remain largely unknown.
Methods
In vitro and in vivo assays were used to investigate the function of FYN. FYN, TOPK, p-TOPK expression in GC specimens were detected by immunohistochemistry. Phosphoproteomics assays identify TOPK downstream substrate molecules. The molecular mechanism was determined using COIP assays, pull-down assays, immunofluorescence co-localization assays, western blotting, 32p-labeled isotope radioautography assays, vitro kinase assays ,and TOPK knockout mice.
Results
FYN was found to be significantly upregulated in GC as well as in GC cells. Knockdown of FYN expression markedly attenuated the malignant phenotype of GC cells in vitro and in vivo. Mechanistically, we identified TOPK/PBK as a novel downstream substrate of FYN, FYN directly phosphorylates TOPK at Y272. One phosphospecific antibodies against Y272 was developed to validate the phosphorylation of TOPK by FYN. Moreover, the TOPK-272F mutation impaired the interaction between TOPK and FYN, leading to disappeared TOPK phosphorylation. Consistently, human GC tissues displayed increased p-TOPK(Y272), which correlated with poor survival. Phosphoproteomics results showed a significant downregulation of both HSPB1 and p-HSPB1(ser15) in TOPK-knockdown cells, which was confirmed by TOPK-konckout mice.
Conclusions
FYN directly binds to TOPK in GC cells and phosphorylates TOPK at the Y272, which leads to proliferation and metastasis of GC. FYN-TOPK axis facilitates GC progression by phosphorylating HSPB1 at S15. Collectively, our study elucidates the pivotal role of the FYN-TOPK-HSPB1 cascade in GC.
Publisher
Research Square Platform LLC
Reference48 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA Cancer J Clin,2021
2. Hallmarks of cancer: the next generation;Hanahan D;Cell,2011
3. HER2-targeted therapies in gastric cancer;Zhu Y;Biochim Biophys Acta Rev Cancer,2021
4. Anti-angiogenic therapies for gastric cancer;Hironaka S;Asia Pac J Clin Oncol,2019
5. Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer;Zeng Y;Semin Cancer Biol,2021